46 records found.
May 22, 2019
Halozyme Announces argenx Has Selected Second Target Under ENHANZE® Technology Collaboration And License Agreement
May 13, 2019
Halozyme To Participate In Bank of America Merrill Lynch Health Care Conference 2019
May 07, 2019
Halozyme Reports First Quarter 2019 Results
Mar 04, 2019
Halozyme To Participate In Upcoming Investor Conferences
Feb 28, 2019
Halozyme Announces FDA Approval Of Herceptin Hylecta(TM)
Feb 21, 2019
Halozyme Reports Fourth Quarter And Full-Year 2018 Results
Feb 07, 2019
Halozyme To Host Fourth Quarter And Full-Year 2018 Financial Results Webcast And Conference Call
Feb 04, 2019
argenx and Halozyme Enter Global Collaboration and License Agreement for ENHANZE® Technology
Jan 09, 2019
Halozyme Provides 2019 Pipeline Update And Financial Guidance At 37th Annual JP Morgan Healthcare Conference
Dec 26, 2018
Halozyme Therapeutics To Present At The 37th Annual J.P. Morgan Healthcare Conference
Nov 06, 2018
Halozyme Names Albert Kildani As Vice President Investor Relations And Corporate Communications
Oct 30, 2018
Halozyme Licenses New ENHANZE® Targets For $25 Million Upfront Payment, Future Milestones And Royalties
Oct 25, 2018
Halozyme Announces First Clinical Dosing In Bristol-Myers Squibb's Phase 1 Trial Of BMS-986179 With Enhanze® Technology
Oct 22, 2018
Halozyme Provides Summary Results Of Data For PEGPH20 Combination Treatments Presented At ESMO 2018 Congress
Oct 10, 2018
Halozyme To Host Third Quarter 2018 Financial Results Conference Call
Oct 04, 2018
Halozyme Publication In The Journal Clinical Cancer Research Highlights New Nonclinical Data Supporting Multiple Effects Of PEGPH20 On The Tumor Microenvironment
Sep 20, 2018
Halozyme Therapeutics To Participate In Upcoming Investor Conference
Sep 17, 2018
Halozyme Announces Approval Of Subcutaneous Formulation Of Trastuzumab (Herceptin®) In Canada
Sep 10, 2018
Halozyme Appoints Bernadette Connaughton To Board Of Directors
Aug 22, 2018
Halozyme Therapeutics To Participate In Upcoming Investor Conferences

Pages